touchSATELLITE SYMPOSIUM Considering the complete picture in neuromyelitis optica spectrum disorder: Optimizing diagnosis and management to improve patient outcomes
Watch three leading experts discuss diagnosis, treatment and care provision for patients with neuromyelitis optica spectrum disorder (NMOSD), with updates on the latest data for immunotherapy treatment options and guidance on how to support the holistic management of patients through multidisciplinary teams.
Prof. Sean Pittock
Mayo Clinic, Rochester, MN, USA
CHAIR
Panelists:
Prof. Sean Pittock opens the virtual symposium and sets the scene for this discussion on optimizing diagnosis and management for patients with NMOSD.
Prof. Sean Pittock and Dr Amy Kunchok discuss the diagnosis of NMOSD, with particular focus on MRI findings and testing for AQP4-IgG.
Prof. Sean Pittock and Prof. Dean Wingerchuk review the latest data for immunotherapies for NMOSD, and describe the various factors that influence treatment choice.
The three faculty discuss the importance of a holistic approach to therapy for patients with NMOSD, encompassing the complexity and wide range of symptoms associated with NMOSD and the role of multidisciplinary teams in supporting patient care.
The three expert faculty answer important questions raised by our audience on the diagnosis and treatment of patients with NMOSD.
Overview & Learning Objectives
Overview
In this touchSATELLITE SYMPOSIUM activity, leading experts in neuromyelitis optica spectrum disorder (NMOSD) discuss the importance of making an accurate and timely diagnosis, as well as the need for appropriate application of the latest data for immunotherapies. They go on to highlight how multidisciplinary teams can support the holistic management of patients with NMOSD for improved outcomes.
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of neurologists, neuro-immunologists, neuroradiologists and ophthalmologists, including neuro-ophthalmologists and specialist neurology nurses, who are active in the management of patients with NMOSD.
Disclosures
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Faculty
Prof. Sean Pittock discloses: Advisory board and panel fees from Alexion Pharmaceuticals Inc., F. Hoffmann-La Roche AG, Genentech and UCB Pharma. Consultant fees from Alexion Pharmaceuticals Inc., EUROIMMUN, MedImmune/Viela Bio (all compensation paid directly to the Mayo Clinic); Prime Therapeutics, Roche/Genentech, Sage Therapeutics, UCB Pharma (personal compensation); Astellas Pharma Inc (compensation to the Mayo Clinic and personal). Grants and research support from AEA, Alexion Pharmaceuticals Inc., Grifols, Guthy-Jackson Charitable Foundation, MedImmune/Viela Bio and National Institutes of Health (all compensation is paid directly to the Mayo Clinic).
Dr Amy Kunchok discloses: Advisory board or panel fees from Genentech.
Prof. Dean Wingerchuk discloses: Advisory board or panel fees from Biogen, Genentech, Horizon Therapeutics, Mitsubishi Tanabe Pharma Corp., Roche, UCB Pharma and Viela Bio. Grants and research support from Alexion Pharmaceuticals Inc. and Terumo BCT Inc.
Content reviewer
Janice Yvonne Maldonado, MD has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact cpdsupport@usf.eduÂ
Accreditations
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Advanced Practice Providers
Physician Assistants may claim a maximum of 1.25Â Category 1Â credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 24 March 2022. Date credits expire: 24 March 2023.
If you have any questions regarding credit please contact cpdsupport@usf.edu
Learning Objectives
After watching this activity, participants should be better able to:
- Describe the clinical manifestations of neuromyelitis optica spectrum disorder (NMOSD), the typical MRI findings and differential diagnoses
- Analyse the treatment options for the prevention of NMOSD attacks and their selection criteria
- Determine strategies for the holistic management of the broad range of symptoms experienced by patients with NMOSD
Faculty & Disclosures
Prof. Sean Pittock
Mayo Clinic, Rochester, MN, USA
Prof. Sean Pittock is Director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology and the Mayo Clinic Neuroimmunology Research Laboratory in Rochester, MN, USA. read more
His specific areas of focus include multidisciplinary, collaborative research into autoimmune neurological disorders, neuromyelitis optica spectrum disorder, and autoimmune gastrointestinal dysmotility.
Prof. Sean Pittock discloses: Advisory board and panel fees from Alexion Pharmaceuticals Inc., F. Hoffmann-La Roche AG, Genentech and UCB Pharma. Consultant fees from Alexion Pharmaceuticals Inc., EUROIMMUN, MedImmune/Viela Bio (all compensation paid directly to the Mayo Clinic); Prime Therapeutics, Roche/Genentech, Sage Therapeutics, UCB Pharma (personal compensation); Astellas Pharma Inc (compensation to the Mayo Clinic and personal). Grants and research support from AEA, Alexion Pharmaceuticals Inc., Grifols, Guthy-Jackson Charitable Foundation, MedImmune/Viela Bio and National Institutes of Health (all compensation is paid directly to the Mayo Clinic).
Dr Amy Kunchok
Cleveland Clinic, Cleveland, OH, USA
Dr Amy Kunchok specializes in multiple sclerosis and autoimmune neurological disorders, and is the director of the autoimmune neurology program at the Cleveland Clinic.
Dr Amy Kunchok discloses: Advisory board or panel fees from Genentech.
Prof. Dean Wingerchuk
Mayo Clinic, Phoenix and Scottsdale, AZ, USA
Prof. Dean Wingerchuk is a neurologist and clinical epidemiologist with specialty expertise in neuroimmunology, and is Professor and Chair of the Department of Neurology at Mayo Clinic in Phoenix and Scottsdale in Arizona, USA. His clinical and research interests focus on neuromyelitis optica spectrum disorder and multiple sclerosis.Â
Prof. Dean Wingerchuk discloses: Advisory board or panel fees from Biogen, Genentech, Horizon Therapeutics, Mitsubishi Tanabe Pharma Corp., Roche, UCB Pharma and Viela Bio. Grants and research support from Alexion Pharmaceuticals Inc. and Terumo BCT Inc.
Register to touchOPHTHALMOLOGY for FREE
- Peer-reviewed journals and expert opinions
- Interactive CME and e-learning modules
- Video conference highlights